Doctors' Choice names top journal ads

Share this article:
Doctors' Choice names top journal ads
Doctors' Choice names top journal ads

The Association of Medical Media (AMM) has announced 13 finalists in its The Doctors' Choice awards for best journal ads.

According to the AMM, 5,742 docs reviewed 327 ads, representing the 200 most widely advertised products in 2007. Ad criteria for judging included the “ability to communicate clearly and quickly, help with clinical decisions, prompt seeking more information or re-examining treatment, generate interest, add to information provided by company sales reps and underscore the value of the product prescribed,” according to an AMM statement.

The agencies and their respective clients are:

  • Ferguson, for Roche
  • AbelsonTaylor, for Scios and Takeda
  • Topin & Associates, for Dusa
  • GSW Worldwide, for Lilly
  • MedThink, for Salix
  • Draftfcb Healthcare, for Merck and Boehringer Ingelheim 
  • Harrison and Star, for Genentech
  • Corbett Worldwide, for Alcon
  • Giant, for Actelion

Winners will be announced at a luncheon at The Palace Hotel on Sept. 24, in New York City.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...